Merrill has Onyx at neutral

Onyx Pharmaceuticals, Inc. was rated at neutral by Merrill Lynch analyst Eric Ende after Pfizer's data for Sutent in kidney cancer that is likely to make the drug the standard of care. With Nexavar sales possibly lower than expected, an expanded label is important. Shares of the Emeryville, Calif.-based biopharmaceutical company were down $3.00, or 15.14%, at $16.82 on volume of 13,206,166 shares versus the three-month running average of 781,997 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.